ObsEva (OBSV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock OBSV vs. OKUR, KZR, ITRM, RNTX, ENLV, ALXO, ADAP, GBIO, IXHL, and FGENShould you be buying ObsEva stock or one of its competitors? The main competitors of ObsEva include OnKure Therapeutics (OKUR), Kezar Life Sciences (KZR), Iterum Therapeutics (ITRM), Rein Therapeutics (RNTX), Enlivex Therapeutics (ENLV), ALX Oncology (ALXO), Adaptimmune Therapeutics (ADAP), Generation Bio (GBIO), Incannex Healthcare (IXHL), and FibroGen (FGEN). These companies are all part of the "pharmaceutical products" industry. ObsEva vs. Its Competitors OnKure Therapeutics Kezar Life Sciences Iterum Therapeutics Rein Therapeutics Enlivex Therapeutics ALX Oncology Adaptimmune Therapeutics Generation Bio Incannex Healthcare FibroGen OnKure Therapeutics (NASDAQ:OKUR) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends. Is OKUR or OBSV more profitable? OnKure Therapeutics' return on equity of -49.13% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets OnKure TherapeuticsN/A -49.13% -45.72% ObsEva N/A -416.36%-92.01% Which has preferable earnings & valuation, OKUR or OBSV? OnKure Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnKure TherapeuticsN/AN/A-$52.67M-$5.26-0.42ObsEvaN/AN/A-$58.38M-$0.92N/A Which has more volatility and risk, OKUR or OBSV? OnKure Therapeutics has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Do analysts recommend OKUR or OBSV? OnKure Therapeutics currently has a consensus target price of $32.33, suggesting a potential upside of 1,369.70%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe OnKure Therapeutics is more favorable than ObsEva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer OKUR or OBSV? In the previous week, ObsEva had 2 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for ObsEva and 0 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score. Company Overall Sentiment OnKure Therapeutics Neutral ObsEva Neutral Do institutionals & insiders have more ownership in OKUR or OBSV? 91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 17.9% of OnKure Therapeutics shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryOnKure Therapeutics beats ObsEva on 9 of the 13 factors compared between the two stocks. Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBSV vs. The Competition Export to ExcelMetricObsEvaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.94M$724.08M$5.52B$9.35BDividend YieldN/A4.84%4.74%4.14%P/E Ratio0.001.3729.0523.78Price / SalesN/A25.69444.6497.50Price / CashN/A19.5624.4827.20Price / BookN/A6.688.365.61Net Income-$58.38M-$3.67M$3.25B$265.26M ObsEva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050News CoverageGap DownOKUROnKure Therapeutics2.8048 of 5 stars$2.31+1.1%$32.33+1,302.1%N/A$31.75MN/A-0.45N/APositive NewsGap UpKZRKezar Life Sciences3.4853 of 5 stars$4.30-1.4%$39.50+819.2%-33.8%$31.47M$7M-0.4060Negative NewsAnalyst DowngradeShort Interest ↑ITRMIterum Therapeutics1.5755 of 5 stars$0.78-0.6%$9.00+1,061.3%-39.0%$31.32MN/A-0.7910Upcoming EarningsShort Interest ↑Gap UpRNTXRein TherapeuticsN/A$1.41-3.4%N/AN/A$31.24MN/A-0.499Positive NewsENLVEnlivex Therapeutics2.4904 of 5 stars$1.36+7.9%$10.00+635.3%+8.2%$30.98MN/A-1.9870Short Interest ↑Gap DownALXOALX Oncology3.2402 of 5 stars$0.60-4.5%$3.30+451.8%-81.9%$30.76MN/A-0.2340Gap DownADAPAdaptimmune Therapeutics2.476 of 5 stars$0.12+15.0%$1.35+1,075.4%-93.2%$30.22M$178.03M-0.42490Upcoming EarningsGap UpHigh Trading VolumeGBIOGeneration Bio3.7035 of 5 stars$4.48-4.8%$80.00+1,687.7%-85.8%$30.00M$24.56M-0.41150Upcoming EarningsGap DownIXHLIncannex Healthcare0.2623 of 5 stars$1.02-14.7%N/A-79.0%$29.87M$10K-0.843Gap DownFGENFibroGen4.3986 of 5 stars$7.28+1.0%$250.00+3,333.6%-35.6%$29.53M$29.62M-2.92570Upcoming Earnings Related Companies and Tools Related Companies OnKure Therapeutics Alternatives Kezar Life Sciences Alternatives Iterum Therapeutics Alternatives Rein Therapeutics Alternatives Enlivex Therapeutics Alternatives ALX Oncology Alternatives Adaptimmune Therapeutics Alternatives Generation Bio Alternatives Incannex Healthcare Alternatives FibroGen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBSV) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Create New Advertiser | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
